Median Technologies appoints Vivian Wang as General Manager, China and Takashi Hayashi as Managing Director, Japan

Sophia Antipolis, France

Press release – For immediate release – 5:45 CEST

  • Vivian Wang and Takashi Hayashi will strengthen Median’s growth in Asia.
  • With these appointments, and the recently announced opening of its subsidiary in Hong Kong, Median intends to significantly invest in and grow its business in the Asian market.

Median Technologies, The Imaging Phenomics Company® today announces the appointment of Vivian Wang as General Manager, China and the appointment of Takashi Hayashi as Managing Director, Japan.

As General Manager of China, Ms. Wang is responsible for scaling Median’s operations and commercial teams.  As the General Manager, she will ensure the execution of the strategic plan across Greater China and the delivery of key company and customer milestones.

Vivian previously worked at Philips Healthcare where she spent a significant part of her career as the Business Leader for healthcare informatics, in which role she developed short-term and long-term business strategy, localized solution portfolio, new product introduction, distributor channel, clinical application and marketing communication strategy for the Greater China market. Vivian had direct P&L responsibility and used her experience to understand the software and healthcare markets in China, the Ministry of Health and the regulatory pathways for new product development as well as building a strong network of Key Opinion Leaders.

Vivian graduated from the Guanghua School of Management, Peking University.

I am so pleased to join Median Technologies as one of the leadership members. As a healthcare marketer, I recognize Median’s excellent corporate culture, comprehensive edge-cutting solutions, which I believe will impact our doctors’ ability to provide precise therapy and improve the patient experience. The China market provides a growing opportunity for our business, and I look forward to further developing and extending Median’s global network,” said Ms. Wang.

As Managing Director, Japan, Takashi Hayashi is responsible for the development and scaling of Median’s business in Japan.

Mr. Hayashi has nearly 30 years of professional experience in the pharmaceutical industry, where he was at a Contract Research Organization (CRO). He has over 13 years of research and business experiences in clinical trials related to pharma/biotech products and health/functional foods.

Previously, Takashi served as Director, Business Development and Key Accounts Asia-Pacific and Japan Country Manager, at BioTelemetry Research, the Research Division of BioTelemetry, Inc.  Prior to BioTelemetry Research, he also held senior management positions as the Operating Officer and Director for Sales, Marketing & Business Development at Ina Research Inc., a leading Japanese CRO, as well as serving as the President & Chief Operating Officer at its Philippine subsidiary, INA RESEARCH PHILIPPINES, INC.

Takashi holds a Bachelor of Science in Life Science from the Tokyo College of Medico-Pharmaco Technology (Japan) and Pacific Western University (off-campus, Hawaii). He is also a part-time researcher at the Department of Pharmacology, School of Medicine in Toho University, Japan.

“As a professional business developer and innovator, I am very honored to be joining the Median organization.  I am also happy and excited to deliver outstanding Median services, expertise and technologies to pharmaceutical and healthcare companies in Japan to help with the development of a healthier world,” said Mr. Hayashi.

The Asian market represents a significant development opportunity for Median’s clinical trials and patient care business lines. Both Vivian’s and Takashi’s in-depth knowledge of the China and Japan markets will be instrumental for strengthening our position in this region. We are very excited to welcome them to our company,” said Jeanne Hecht, Chief Operating Officer of Median Technologies. “Along with these two major appointments, we recently announced the opening of our new subsidiary in Hong Kong, which will allow the company to directly access the Asian market. We are also leveraging our Chinese Investor, FURUI, to build and further develop KOL networks for our patient care business line,” she added.

Download 20171019_PR_Appointments_AsiaPacific_final.pdf